Key result
Adiposity plus prediabetes is linked to ~38% higher risk of metabolic progression versus prediabetes alone.
Why the study?
The 2026 AHA/ACC/ADA/ASN guideline defines CKM stage 1 by excess or dysfunctional adiposity, but whether specific adiposity and glycemic patterns distinguish subsequent risk was uncertain.
Do combined adiposity and glycemic patterns distinguish subsequent risk of metabolic progression, hypertension, and cardiovascular disease in adults aged 45–79 years meeting CKM stage 1 criteria?
Cohort (n=1,824)
Yes
Do combined adiposity and glycemic patterns distinguish subsequent risk of metabolic progression, hypertension, and cardiovascular disease in adults aged 45–79 years meeting CKM stage 1 criteria?
Combined assessment of adiposity and glycemic patterns identifies significant prognostic heterogeneity for metabolic progression, hypertension, and CVD among adults classified as CKM stage 1.
Adiposity plus prediabetes was associated with metabolic progression in CKM stage 1; hypothesis-generating for refined staging, prospective validation required.
Background The 2026 AHA/ACC/ADA/ASN guideline defines cardiovascular-kidney-metabolic (CKM) stage 1 by excess or dysfunctional adiposity. Whether adiposity and glycemic patterns distinguish subsequent risk is uncertain. Methods Adults aged 45–79 years meeting measured stage 1 criteria were studied in CHARLS and CHNS. Four patterns combined body mass index (BMI), waist circumference, and prediabetes. Modified Poisson models estimated risk ratios (RRs). Progression and hypertension models used censoring weights; cumulative self-reported cardiovascular disease (CVD) models used baseline-covariate imputation. The nonglycemic composite was a key secondary outcome. NHANES assessed reclassification with ancestry-appropriate thresholds and age–sex standardization. Chinese cohorts lacked albuminuria and subclinical CVD assessment. Results In CHARLS (model n = 965), adiposity plus prediabetes was associated with metabolic progression versus prediabetes only (RR, 1.38; 95% CI, 1.18–1.61). Corresponding RRs were 1.45 (1.21–1.74) for nonglycemic progression and 1.55 (1.21–1.98) for CHNS hypertension. Among 1824 participants, concordant BMI and waist adiposity was associated with cumulative reported CVD through 2020 (RR, 1.83; 95% CI, 1.23–2.71). CVD associations attenuated in complete-case models and after additional adjustment for metabolic measures. Standardized NHANES reclassification ranged from 0.8% to 9.0%. Conclusions Adiposity and glycemic patterns identified prognostic heterogeneity among adults meeting measured CKM stage 1 criteria, supporting joint assessment of these features.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) conducted a cohort in Cardiovascular-kidney-metabolic (CKM) stage 1 (n=1,824). Adiposity plus prediabetes / concordant BMI and waist adiposity vs. Prediabetes only was evaluated on Metabolic progression (RR 1.38, 95% CI 1.18-1.61). Adiposity plus prediabetes was associated with higher risk of metabolic progression versus prediabetes only (RR 1.38; 95% CI 1.18-1.61) in CKM stage 1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: